1,4-Benzoquinone is a topoisomerase II poison

Biochemistry

Volumn 43, Issue 23, 2004, Pages 7563-7574

  Lindsey Jr , R Hunter ^a   Bromberg, Kenneth D ^a,c   Felix, Carolyn A ^b   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE; DNA; DRUG PRODUCTS; ENZYMES; METABOLITES; PHENOLS;

DNA DAMAGE; HUMAN CARCINOGEN; REACTION BUFFERS; REDUCING AGENTS;

BIOCHEMISTRY;

1,4 BENZOQUINONE; BENZENE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) IIALPHA; ETOPOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME BREAKAGE; DNA CLEAVAGE; DNA DAMAGE; DRUG POTENCY; ENZYME SUBUNIT; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMOGENESIS; METABOLITE; PRIORITY JOURNAL;

BASE SEQUENCE; BENZOQUINONES; CATALYSIS; CELLS, CULTURED; DITHIOTHREITOL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, CIRCULAR; GLUTATHIONE; HUMANS; PLASMIDS;

EID: 2942555034     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi049756r     Document Type: Article

References (114)

1. Fishbein, L. (1992) Exposure from occupational versus other sources, Scand. J. Work Environ. Health 18 (Suppl. 1), 5-16.
2. Agency for Toxic Substances and Disease Registry (1997) Toxicological profile for benzene, U.S. Department of Health and Human Services, Public Health Service.
3. International Agency for Research on Cancer (1989) Benzene, Vol. 45, IARC Scientific Publications, Lyon, France.
4. Wallace, L. A. (1989) Major sources of benzene exposure, Environ. Health Perspect. 82, 165-169.
5. International Programme Chemical Safety IPCS (1993) Environmental Health Criteria, 150. Benzene, World Health Organization, Geneva, Switzerland.
6. Ott, M. G., Townsend, J. C., Fishbeck, W. A., and Langner, R. A. (1978) Mortality among individuals occupationally exposed to benzene, Arch. Environ. Health. 33, 3-10.
7. Rinsky, R. A., Smith, A. B., Homung, R., Filloon, T. G., Young, R. J., Okun, A. H., and Landrigan, P. J. (1987) Benzene and leukemia. An epidemiologic risk assessment, N. Engl. J. Med. 316, 1044-1050.
8. Crump, K. S. (1994) Risk of benzene-induced leukemia: a sensitivity analysis of the pliofilm cohort with additional follow-up and new exposure estimates, J. Toxicol. Environ. Health. 42, 219-242.
9. Paxton, M. B., Chinchilli, V. M., Brett, S. M., and Rodricks, J. V. (1994) Leukemia risk associated with benzene exposure in the pliofilm cohort. II. Risk estimates, Risk. Anal. 14, 155-161.
10. Snyder, R., and Kalf, G. F. (1994) A perspective on benzene leukemogenesis, Crit. Rev. Toxicol. 24, 177-209.
11. Hayes, R. B., Yin, S. N., Dosemeci, M., Li, G. L., Wacholder, S., Travis, L. B., Li, C. Y., Rothman, N., Hoover, R. N., and Linet, M. S. (1997) Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group, J. Natl. Cancer Inst. 89, 1065-1071.
12. Sabourin, P. J., Bechtold, W. E., Griffith, W. C., Birnbaum, L. S., Lucier, G., and Henderson, R. F. (1989) Effect of exposure concentration, exposure rate, and route of administration on metabolism of benzene by F344 rats and B6C3F1 mice, Toxicol. Appl. Pharmacol. 99, 421-444.
13. Savitz, D. A., and Andrews, K. W. (1997) Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers, Am. J. Ind. Med. 31, 287-295.
14. Golding, B. T., and Watson, W. P. (1999) in Exocyclic DNA Adducts in Mutagenesis and Carcinogenesis (Singer, B., and Bartsch, H., Eds.) pp 75-88, IARC Scientific Publications, Lyon.
15. Irons, R. D. (2000) Molecular models of benzene leukemogenesis, J. Toxicol. Environ. Health A 61, 391-397.
16. Lovern, M. R., Cole, C. E., and Schlosser, P. M. (2001) A review of quantitative studies of benzene metabolism, Crit. Rev. Toxicol. 31, 285-311.
17. Snyder, R., and Hedli, C. C. (1996) An overview of benzene metabolism, Environ. Health Perspect. 104 (Suppl. 6), 1165-1171.
18. Ross, D. (2000) The role of metabolism and specific metabolites in benzene-induced toxicity: evidence and issues, J. Toxicol. Environ. Health A 61, 357-372.
19. Wiemels, J. L., Pagnamenta, A., Taylor, G. M., Eden, O. B., Alexander, F. E., and Greaves, M. F. (1999) A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators, Cancer Res. 59, 4095-4099.
20. Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C., Le Beau, M. M., and Smith, M. T. (1999) Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia, Blood 94, 803-807.
21. Smith, M. T. (1999) Benzene, NQO1, and genetic susceptibility to cancer, Proc. Natl. Acad. Sci. U.S.A. 96, 7624-7626.
22. Smith, M. T., Wang, Y., Skibola, C. F., Slater, D. J., Lo Nigro, L., Nowell, P. C., Lange, B. J., and Felix, C. A. (2002) Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children, Blood 100, 4590-4593.
23. Smith, M. T., Wang, Y., Kane, E., Rollinson, S., Wiemels, J. L., Roman, E., Roddam, P., Cartwright, R., and Morgan, G. (2001) Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults, Blood 97, 1422-1426.
24. Smith, M. T. (1996) The mechanism of benzene-induced leukemia: a hypothesis and speculations on the causes of leukemia, Environ. Health Perspect. 104 (Suppl. 6), 1219-1225.
25. Hutt, A. M., and Kalf, G. F. (1996) Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene, Environ. Health Perspect. 104 (Suppl. 6), 1265-1269.
26. Ludewig, G., Dogra, S., and Glatt, H. (1989) Genotoxicity of 1,4-benzoquinone and 1,4-naphthoquinone in relation to effects on glutathione and NAD(P)H levels in V79 cells, Environ. Health Perspect. 82, 223-228.
27. Sze, C. C., Shi, C. Y., and Ong, C. N. (1996) Cytotoxicity and DNA strand breaks induced by benzene and its metabolites in Chinese hamster ovary cells, J. Appl. Toxicol. 16, 259-264.
28. Nakayama, A., Koyoshi, S., Morisawa, S., and Yagi, T. (2000) Comparison of the mutations induced by p-benzoquinone, a benzene metabolite, in human and mouse cells, Mutat. Res. 470, 147-153.
29. Erexson, G. L., Wilmer, J. L., and Kligerman, A. D. (1985) Sister chromatid exchange induction in human lymphocytes exposed to benzene and its metabolites in vitro, Cancer Res. 45, 2471-2477.
30. Hiraku, Y., and Kawanishi, S. (1996) Oxidative DNA damage and apoptosis induced by benzene metabolites, Cancer Res. 56, 5172-5178.
31. Winn, L. M. (2003) Homologous recombination initiated by benzene metabolites: a potential role of oxidative stress, Toxicol. Sci. 72, 143-149.
32. Shen, Y., Shen, H. M., Shi, C. Y., and Ong, C. N. (1996) Benzene metabolites enhance reactive oxygen species generation in HL60 human leukemia cells, Hum. Exp. Toxicol. 15, 422-427.
33. Kuo, M. L., Shiah, S. G., Wang, C. J., and Chuang, S. E. (1999) Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis, Mol. Pharmacol. 55, 894-901.
34. Rappaport, S. M., Waidyanatha, S., Qu, Q., Shore, R., Jin, X., Cohen, B., Chen, L. C., Melikian, A. A., Li, G., Yin, S., Yan, H., Xu, B., Mu, R., Li, Y., Zhang, X., and Li, K. (2002) Albumin adducts of benzene oxide and 1,4-benzoquinone as measures of human benzene metabolism, Cancer Res. 62, 1330-1337.
35. Frantz, C. E., Chen, H., and Eastmond, D. A. (1996) Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites, Environ. Health Perspect. 104 (Suppl. 6), 1319-1323.
36. Baker, R. K., Kurz, E. U., Pyatt, D. W., Irons, R. D., and Kroll, D. J. (2001) Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα, Blood 98, 830-833.
37. Chen, H., and Eastmond, D. A. (1995) Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects, Carcinogenesis 16, 2301-2307.
38. Wang, J. C. (1996) DNA Topoisomerases, Annu. Rev. Biochem. 65, 635-692.
39. Burden, D. A., and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme, Biochim. Biophys. Acta 1400, 139-154.
40. Wang, J. C. (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine, Q. Rev. Biophys. 31, 107-144.
41. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells, Biochim. Biophys. Acta 1400, 63-81.
42. Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice, Prog. Nucleic Acids Res. Mol. Biol. 64, 221-253.
43. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell. Biol. 3, 430-440.
44. Wilstermann, A. M., and Osheroff, N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes, Curr. Top. Med. Chem. 3, 321-338.
45. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. (1996) Structure and mechanism of DNA topoisomerase II, Nature 379, 225-232.
46. Goto, T., and Wang, J. C. (1984) Yeast DNA topoisomerase II is encoded by a single-copy, essential gene, Cell 36, 1073-1080.
47. Voelkel-Meiman, K., DiNardo, S., and Sternglanz, R. (1986) Molecular cloning and genetic mapping of the DNA topoisomerase II gene of Saccharomyces cerevisiae, Gene 42, 193-199.
48. Uemura, T., Morikawa, K., and Yanagida, M. (1986) The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases, EMBO J. 5, 2355-2361.
49. Nolan, J. M., Lee, M. P., Wyckoff, E., and Hsieh, T. S. (1986) Isolation and characterization of the gene encoding Drosophila DNA topoisomerase II, Proc. Natl. Acad. Sci. U.S.A. 83, 3664-3668.
50. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., Crooke, S. T., and Mirabelli, C. K. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme, J. Biol. Chem. 262, 16739-16747.
51. Jenkins, J. R., Ayton, P., Jones, T., Davies, S. L., Simmons, D. L., Harris, A. L., Sheer, D., and Hickson, I. D. (1992) Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24, Nucleic Acids Res. 20, 5587-5592.
52. Tan, K. B., Dorman, T. E., Falls, K. M., Chung, T. D., Mirabelli, C. K., Crooke, S. T., and Mao, J. (1992) Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively, Cancer Res. 52, 231-234.
53. Austin, C. A., and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase IIβ, BioEssays 20, 215-226.
54. Heck, M. M., and Eamshaw, W. C. (1986) Topoisomerase II: A specific marker for cell proliferation, J. Cell Biol. 103, 2569-2581.
55. Heck, M. M., Hittelman, W. N., and Eamshaw, W. C. (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle, Proc. Natl. Acad. Sci. U.S.A. 85, 1086-1090.
56. Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., and Hickson, I. D. (1998) Physiological regulation of eukaryotic topoisomerase II, Biochim. Biophys. Acta 1400, 121-137.
57. Grue, P., Grasser, A., Sehested, M., Jensen, P. B., Uhse, A., Straub, T., Ness, W., and Boege, F. (1998) Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells, J. Biol. Chem. 273, 33660-33666.
58. Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster, J. Biol. Chem. 258, 8421-8428.
59. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II, J. Biol. Chem. 258, 15365-15370.
60. Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., and Osheroff, N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate, Biochemistry 28, 6229-6236.
61. Kaufmann, S. H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers, Biochim. Biophys. Acta 1400, 195-211.
62. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs, Biochim. Biophys. Acta 1400, 233-255.
63. Rowley, J. D. (1998) The critical role of chromosome translocations in human leukemias, Annu. Rev. Genet. 32, 495-519.
64. Kaufmann, S. H., Gore, S. D., Miller, C. B., Jones, R. J., Zwelling, L. A., Schneider, E., Burke, P. J., and Karp, J. E. (1998) Topoisomerase II and the response to antileukemic therapy, Leukemia Lymph. 29, 217-237.
65. Sordet, O., Khan, Q. A., Kohn, K. W., and Pommier, Y. (2003) Apoptosis induced by topoisomerase inhibitors, Curr. Med. Chem. Anti-Cancer Agents 3, 271-290.
66. Pommier, Y. (1997) in Cancer Drug Discovery and Development (Teicher, B. A., Ed.) pp 153-174, Humana Press, Inc., Totowa, NJ.
67. Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim. Biophys. Acta 1400, 173-184.
68. Li, T. K., and Liu, L. F. (2001) Tumor cell death induced by topoisomerase-targeting drugs, Annu. Rev. Pharmacol. Toxicol. 41, 53-77.
69. Toonen, T. R., and Hande, K. R. (2001) Topoisomerase II inhibitors, Cancer Chemother. Biol. Response Modif. 19, 129-147.
70. Walker, J. V., and Nitiss, J. L. (2002) DNA topoisomerase II as a target for cancer chemotherapy, Cancer Invest. 20, 570-589.
71. Kreuzer, K. N., and Cozzarelli, N. R. (1979) Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth, J. Bacteriol. 140, 424-435.
72. DeVore, R., Whitlock, J., Hainsworth, T., and Johnson, D. (1989) Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q, Ann. Intern. Med. 110, 740-742.
73. Ratain, M. J., and Rowley, J. D. (1992) Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes, Ann. Oncol. 3, 107-111.
74. Felix, C. A., and Lange, B. J. (1999) Leukemia in infants, Oncologist 4, 225-240.
75. Pui, C. H., and Relling, M. V. (2000) Topoisomerase II inhibitor-related acute myeloid leukaemia, Br. J. Haematol. 109, 13-23.
76. Strick, R., Strissel, P. L., Borgers, S., Smith, S. L., and Rowley, J. D. (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia, Proc. Natl. Acad. Sci. U.S.A. 97, 4790-4795.
77. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors, Med. Pediatr. Oncol. 36, 525-535.
78. Leone, G., Voso, M. T., Sica, S., Morosetti, R., and Pagano, L. (2001) Therapy related leukemias: susceptibility, prevention and treatment, Leuk. Lymphoma 41, 255-276.
79. Smith, M. A., Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., and Vena, D. (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins, J. Clin. Oncol. 17, 569-577.
80. Ross, J. A., Potter, J. D., and Robison, L. L. (1994) Infant leukemia, topoisomerase II inhibitors, and the MLL gene, J. Natl. Cancer Inst. 86, 1678-1680.
81. Ross, J. A., Potter, J. D., Reaman, G. H., Pendergrass, T. W., and Robison, L. L. (1996) Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group, Cancer, Causes Control 7, 581-590.
82. Wang, H., Mao, Y., Chen, A. Y., Zhou, N., LaVoie, E. J., and Liu, L. F. (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation, Biochemistry 40, 3316-3323.
83. Lovett, B. D., Strumberg, D., Blair, I. A., Pang, S., Burden, D. A., Megonigal, M. D., Rappaport, E. F., Rebbeck, T. R., Osheroff, N., Pommier, Y. G., and Felix, C. A. (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints, Biochemistry 40, 1159-1170.
84. Zhou, N., Xiao, H., Li, T. K., Nur, E. K. A., and Liu, L. F. (2003) DNA damage-mediated apoptosis induced by selenium compounds, J. Biol. Chem. 278, 29532-29537.
85. Bender, R. P., Lindsey, R. H., Jr., Burden, D. A., and Osheroff, N. (2004) N-acetyl-p-benzoquinone Imine, the Toxic Metabolite of Acetaminophen, is a Topoisomerase II Poison, Biochemistry 43, 3731-3739.
86. Worland, S. T., and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae, J. Biol. Chem. 264, 4412-4416.
87. Elsea, S. H., Hsiung, Y., Nitiss, J. L., and Osheroff, N. (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine, J. Biol. Chem. 270, 1913-1920.
88. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints, Biochemistry 36, 5934-5939.
89. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage, J. Biol. Chem. 273, 17643-17650.
90. O'Reilly, E. K., and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents, Biochemistry 41, 7989-7997.
91. Bromberg, K. D., Hendricks, C., Burgin, A. B., and Osheroff, N. (2002) Human topoisomerase IIα possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5′ covalently activated oligonucleotide substrates to study enzyme mechanism, J. Biol. Chem. 277, 31201-31206.
92. Slater, D. J., Hilgenfeld, E., Rappaport, E. F., Shah, N., Meek, R. G., Williams, W. R., Lovett, B. D., Osheroff, N., Autar, R. S., Ried, T., and Felix, C. A. (2002) MLL-SEPT1N6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X.; 11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPT1N6 rearrangement is a DNA topoisomerase II cleavage site, Oncogene 21, 4706-4714.
93. Sander, M., and Hsieh, T. S. (1985) Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site, Nucleic Acids Res. 13, 1057-1072.
94. Corbett, A. H., Zechiedrich, E. L., and Osheroff, N. (1992) A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage, J. Biol. Chem. 267, 683-686.
95. Kingma, P. S., and Osheroff, N. (1997) Apurinic sites are position-specific topoisomerase II poisons, J. Biol. Chem. 272, 1148-1155.
96. Byl, J. A., Fortune, J. M., Burden, D. A., Nitiss, J. L., Utsugi, T., Yamada, Y., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement, Biochemistry 38, 15573-15579.
97. Burgin, A. B., Jr., Huizenga, B. N., and Nash, H. A. (1995) A novel suicide substrate for DNA topoisomerases and site-specific recombinases, Nucleic Acids Res. 23, 2973-2979.
98. Shaw, J. L., Blanco, J., and Mueller, G. C. (1975) Simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells, Anal. Biochem. 65, 125-131.
99. Subramanian, D., Kraut, E., Staubus, A., Young, D. C., and Muller, M. T. (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan, Cancer Res. 55, 2097-2103.
100. Cavalieri, E. L., Stack, D. E., Devanesan, P. D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S. L., Patil, K. D., Gross, M. L., Gooden, J. K., Ramanathan, R., Cerny, R. L., and Rogan, E. G. (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators, Proc. Natl. Acad. Sci. U.S.A. 94, 10937-10942.
101. Snyder, R. (2000) Overview of the toxicology of benzene, J. Toxicol. Environ. Health A 61, 339-346.
102. Kingma, P. S., and Osheroff, N. (1998) Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing: abasic lesions as a tool to dissect enzyme mechanism, J. Biol. Chem. 273, 17999-18002.
103. Cline, S. D., and Osheroff, N. (1999) Cytosine arabinoside (araC) lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes, J. Biol. Chem. 274, 29740-29743.
104. Cline, S. D., Jones, W. R., Stone, M. P., and Osheroff, N. (1999) DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison, Biochemistry 38, 15500-15507.
105. Sabourin, M., and Osheroff, N. (2000) Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions, Nucleic. Acids Res. 28, 1947-1954.
106. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide, Nucleic Acids Res. 19, 5973-5980.
107. Capranico, G., and Binaschi, M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons, Biochim. Biophys. Acta 1400, 185-194.
108. Osheroff, N. (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide, Biochemistry 28, 6157-6160.
109. Bromberg, K. D., Burgin, A. B., and Osheroff, N. (2003) A two drug model for etoposide action against human topoisomerase IIα, J. Biol. Chem. 278, 7406-7412.
110. Corbett, A. H., and Osheroff, N. (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs, Chem. Res. Toxicol. 6, 585-597.
111. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage, J. Biol. Chem. 266, 14585-14592.
112. Bromberg, K. D., Burgin, A. B., and Osheroff, N. (2003) Quinolone action against human topoisomerase IIα: stimulation of enzyme-mediated double-stranded DNA cleavage, Biochemistry 42, 3393-3398.
113. Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N. K., Lovett, B. D., Nowell, P. C., Blair, I. A., and Rebbeck, T. R. (1998) Association of CYP3A4 genotype with treatment-related leukemia, Proc. Natl. Acad. Sci. U.S.A. 95, 13176-13181,
114. van Maanen, J. M., Retel, J., de Vries, J., and Pinedo, H. M. (1988) Mechanism of action of antitumor drug etoposide: a review, J. Natl. Cancer Inst. 80, 1526-1533.